NEW YORK, Oct. 17, 2005 (PRIMEZONE) -- A Manhattan Pharmaceuticals, Inc. (AMEX:MHA) news release issued today at 7:44 a.m. (ET) (Oct. 17, 2005) contained errors in the table of VAS scores. The correct version of the entire release follows.
Manhattan Pharmaceuticals, Inc. (AMEX:MHA) announced preliminary results from two Phase I clinical trials of oleoyl-estrone (OE), an experimental, orally administered small molecule in development for the treatment of obesity. The data were presented in a poster yesterday at the 2005 Annual Scientific Meeting of NAASO, The Obesity Society, in Vancouver, BC.
The Phase I study, conducted in Switzerland, was done in two parts, which consisted of a single dose study and a seven-day repeat dose study. The primary purpose was to assess the safety, tolerability and pharmacokinetics of OE. Some efficacy parameters were included and measured in the repeat dose component of the study.
Highlights of the study included:
-- OE was generally well tolerated at all doses investigated.
-- OE demonstrated evidence of reduction in weight.
-- OE demonstrated evidence of: reduction in desire to eat and
hunger level, reduction in prospective food consumption, reduced
fasting glucose, reduced LDL cholesterol and changes in other
key measures.
-- There were no clinically significant changes in the physical
exams, vital signs, ECGs, coagulation or liver function tests.
-- No serious adverse events were reported. Clinical laboratory
findings included reversible, dose-dependent elevations in
estrone and estradiol levels as well as reductions in
testosterone levels.
Phase Ia was a dose-escalating study to measure OE's pharmacokinetic profile, safety and tolerability in 36 obese males and females ages 18-65, with a body mass index greater than 30.0 (a BMI of greater than 30.0 is classified as obese per guidelines from the U.S. Department of Health and Human Services). Twelve of the subjects received placebo and 24 received a single dose of OE in one of six doses ranging from 1mg to 150mg.
Phase Ib measured OE's safety and tolerability in 24 obese volunteers in four cohorts of six patients each who received either placebo or OE in doses ranging from 10mg to 150mg once daily for seven consecutive days. The protocol provided that subjects should maintain their normal diet and level of activity, but required that subjects abstain from consuming alcohol.
The OE-treated groups in the Phase Ib study demonstrated evidence of greater weight loss than the placebo group. Weights were assessed at baseline, Day 15, and Day 28. Weight loss appeared to be maintained for longer periods in the OE groups compared to placebo at Day 28, twenty-one days following cessation of treatment. This data may support the contention that the mechanism of action of OE involves a "resetting" of the ponderostat, or appetite "set point". It also provides a rationale for testing alternative regimens such as low or intermittent dosing.
Average change from baseline weight (in kilograms)
---------------------------------------------------------------------
Placebo 10mg 30mg 100mg 150mg
---- ---- ----- -----
---------------------------------------------------------------------
Day 15
(8 days
following
final
dose) -0.90 (n=8) -0.75 (n=4) -0.18 (n=4) -1.95 (n=4) -1.17 (n=4)
---------------------------------------------------------------------
Day 28
(21 days
following
final
dose) 0.00 (n=6) not -0.53 (n=4) -1.35 (n=4) -0.18 (n=4)
measured
---------------------------------------------------------------------
The OE-treated groups in the Phase Ib study also demonstrated evidence of a reduction in the feeling of desire to eat, hunger level and prospective food consumption as measured by changes in the visual analogue scales (VAS).
Average percent change in VAS scores as measured day 7 vs. baseline
---------------------------------------------------------------------
Placebo 10mg 30mg 100mg 150mg
---- ---- ---- -----
---------------------------------------------------------------------
1. How strong is
your desire to
eat right now? +6.6% +136% -45.67% -40.5% -46.2%
---------------------------------------------------------------------
2. How hungry do
you feel right
now? -9.4% +22% -41.7% -25.8% -43.5%
---------------------------------------------------------------------
3. How much food
could you eat
right now? +2.9% +61.2% -42.1% -39.7% -37.5%
---------------------------------------------------------------------
4. How full do
you feel right
now?(a) +3.07% -13.2% +19.2% -11.1% +48.3%
---------------------------------------------------------------------
(a) Note: In items 1, 2 and 3 increasing VAS scores indicate an increase in desire to eat. In item 4 an increase in VAS score indicates an increase in fullness.
OE was generally well tolerated. The most common side effects reported included headache, back pain, and diarrhea. No serious adverse events were reported.
Total mean cholesterol decreased at Day 7 at the 100mg and 150mg dose. Mean HDL-cholesterol increased and mean LDL-cholesterol decreased with a trend toward improvement in the LDL-to-HDL cholesterol ratio, even at the lower doses. Mean glucose concentration decreased in a reversible and dose dependent manner and remained decreased at Day 15. Mean estradiol and estrone levels were elevated, while mean testosterone levels were suppressed, all in a reversible and dose dependent manner. In addition, there were no clinically significant changes in the physical exams, vital signs, ECG's, coagulation or liver function tests.
The preliminary plasma concentration-time profiles show that the plasma concentration of OE did not increase with the administered dose level. There were no significantly elevated plasma concentrations of OE on Day 7, which may indicate that there is no clear accumulation in plasma after daily oral dosing for seven consecutive days. In this small sample study there were no clear differences between the sexes with respect to plasma concentration.
"Given the current crisis that we face with the growing prevalence of obesity, I am encouraged to see signs of efficacy in this study, though the metabolic and hormonal effects merit further study. Obesity and its complications, particularly type 2 diabetes, are rapidly becoming the number one health threat around the globe. Oleoyl-estrone may provide a new treatment option," said J. Larry Jameson, M.D., a leading endocrinologist who is Professor and Chairman of Medicine at Northwestern University Medical School.
"We are excited to have seen this much evidence of benefit in a phase I trial with only 7 days of exposure," said Doug Abel, President and CEO of Manhattan Pharmaceuticals. "We are working closely with our scientific and clinical advisors to interpret this data and finalize study designs. We plan to initiate a phase IIa trial early next year."
The full scientific poster of these results can be viewed on the company's website at www.manhattanpharma.com
ABOUT OLEOYL-ESTRONE
Oleoyl-estrone (OE) is an orally administered small molecule that has been shown to cause significant weight loss in extensive preclinical animal studies, without the need for dietary modifications. Developed by researchers at the University of Barcelona, OE has been tested in both obese and lean rats; treatment with OE resulted in significant weight loss even in the presence of abundant food and water. We believe that OE may prove to be a safe and effective treatment of obesity, potentially representing a significant advantage over currently available anti-obesity medications.
ABOUT OBESITY
Obesity is one of the most common metabolic disorders in the world. Nearly 61% of all Americans are considered to be overweight, and 26% percent are considered to be obese. The World Bank estimates that obesity alone accounts for more than 12% of the U.S. national health care budget. The National Institutes of Health estimated that direct costs for the treatment of obesity in 1988 were in excess of $45 billion and accounted for nearly 8% of the total national cost of health care; a decade later, annual direct costs for the treatment of obesity had risen to $102.2 billion dollars. As these statistics illustrate, obesity is a rapidly growing, costly disease, for which there is currently no effective treatment.
ABOUT MANHATTAN PHARMACEUTICALS, INC.
Manhattan Pharmaceuticals, Inc. (AMEX:MHA), a development stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing OE, an orally administered novel therapeutic for weight loss. To meet the needs of other major, underserved medical markets while lowering development risks, Manhattan Pharmaceuticals is also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, for psoriasis and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures. (http://www.manhattanpharma.com)
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors described in our filings with the Securities and Exchange Commission.